FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

ASTRAZEN

3,498.9
-0.6 (-0.02%)
Updated 03:28 23/07 IST

ASTRAZEN Buy or Sell - FrontPage Forums

2 Users have submitted 2 trade ideas of Rs. 85,948.65 for ASTRAZEN
Disclaimer
100% Bullish
0% Bearish

ASTRAZEN Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See ASTRAZEN Share Price Targets >>

ASTRAZEN Ratings

Long term ASTRAZEN rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live ASTRAZEN message board: Is ASTRAZEN buy or sell? Should I buy ASTRAZEN shares? Why are ASTRAZEN shares falling? Should I invest in ASTRAZEN stock?

  1. Home
  2. ASTRAZEN Forum

ASTRAZEN Share Price Discussion

N
Reputation: 15,595 • Today 2:11 AM
UK briefed on COVID-19 situation in India to review 'red list' travel ban
"It's an Oxford/AstraZeneca vaccine being manufactured under a transfer of technology in India so there can't be any difference in product - between that produced at the Serum Institute of India (SII) or anywhere else," said Shringla.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Today 8:26 AM
CoronaVac vaccine: its results are patchy, but the world can't ignore its usefulness
The latter, developed by the Sinovac Biotech company, is the latest COVID-19 vaccine to be authorised for emergency use by the World Health Organization (WHO). Because of this, the CoronaVac vaccine could have a big role to play in turning the tide of the pandemic.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 22 7:21 AM
Study finds lower antibody activity against delta variant at single dose, but vaccines still work
This virus has spread to at least 90 countries and is 50% more transmissible than the alpha variant (the variant first identified in Kent), which is around 50% more transmissible than the original coronavirus that caused the pandemic.
The Economic Times
Like
Reply
H
Reputation: 5,519 • Jul 22 4:05 AM

Type
Buy
Instrument
ASTRAZEN
Entry Price
₹3,567.5
Price@Trade
₹3,567.5
Target Price
₹3,650
Stop Price
₹3,480
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹178,375 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹3,480
Net P&L
-₹4,375 (-2.45%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 5:02 AM

Update
Stoploss Hit
Exit Price
₹3,480
N
Reputation: 15,595 • Jul 22 2:01 AM
Asian stocks shrug off virus worries; ECB in focus
MSCI's broadest index of Asia-Pacific shares outside Japan followed Wall Street higher and rose 1% with broad gains from Sydney to Seoul and Hong Kong . Japanese markets are closed until Monday.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 21 5:06 AM
Covid-19 pandemic has dimmed the clean power market
Corporate demand for clean electricity is declining for the first time because more employees are working from home than ever before. This is most notable for companies in the RE100, which have all pledged to offset 100% of their electricity consumption with clean energy.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 21 3:06 AM
Australia, under lockdown, sees jump in COVID-19 cases
Victoria state clocked 22 new cases, from nine the day before, its biggest increase since the outbreak began this month, even as it nears its second week of statewide lockdown.
The Economic Times
1
Reply
N
Reputation: 15,595 • Jul 20 4:21 AM
The Beta variant: What scientists know right now
The World Health Organization and the Centers for Disease Control and Prevention have both designated beta as a “variant of concern.”
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 19 1:16 AM
Bharat Biotech dossier under review for Covaxin emergency use listing: WHO
Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave.
The Economic Times
Like
Reply
S
Reputation: 0 • Jul 19 5:56 AM

Type
Buy
Instrument
ASTRAZEN
Entry Price
₹3,517.05
Price@Trade
₹3,517.15
Target Price
₹3,530
Stop Price
₹3,500
Valid Till
Jul 20, 2021 3:20 AM
Margin
₹175,852.5 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹3,500
Net P&L
-₹852.5 (-0.48%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 19 5:57 AM

Update
Trade Entered
Entry Price
₹3,517.05
TrackerBot @trackerbot
Jul 19 8:13 AM

Update
Stoploss Hit
Exit Price
₹3,500
N
Reputation: 15,595 • Jul 19 12:41 PM
AstraZeneca wants Serum Institute of India listed as manufacturing site
“We have requested the addition of Serum Institute of India as an alternative manufacturing site on the Vaxzevria licence,” an AstraZeneca spokesperson told ET. The EMA has approved AstraZenecas Vaxzevria but Covishield, which is made by SII using the same technology, hasnt got the nod.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 16 6:06 AM
India, Bangladesh reaffirm commitment to further strengthen bilateral cooperation
External Affairs Minister S Jaishankar and his Bangladeshi counterpart AK Abdul Momen met in Uzbekistan's capital on the sidelines of an international conference on the challenges and opportunities of regional connectivity in Central and South Asia on Thursday.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 16 3:16 AM
Moderna to join S&P 500, shares jump after hours
Moderna shares rose 6% in extended trade after the announcement. The COVID-19 vaccine maker's stock has surged over 150% this year, elevating its market capitalization to about $100 billion.
The Economic Times
Like
Reply

Type
Buy
Instrument
ASTRAZEN
Entry Price
₹3,530.95
Price@Trade
₹3,530.95
Target Price
₹4,500
Stop Price
₹2,800
Valid Till
Aug 16, 2021 3:20 AM
Margin
₹353,095 approx for 100 Qty
Status
Exited
Exit Price
₹3,544.5
Net P&L
+₹1,355 (+0.38%)

Like
Reply (1)
swap_vert
Trade
See all replies
Sani Singh @sanisingh
Jul 22 4:59 AM

Update
Exited
Exit Price
₹3,544.5
Net P&L
+₹1,355 (+0.38%)
N
Reputation: 15,595 • Jul 16 5:41 AM
India pulled back global supply of COVAX due to surge of cases inside the country: USAID administrator
"When the Delta variant is raging around the world and supply is lacking globally because the Serum Institute of India pulled back hundreds of millions of vaccines that were supposed to go to COVAX because Europe is still in the throes of the pandemic, hopefully coming out of it now with light at the end of the tunnel," USAID Administrator Samantha Power told a Congressional Committee.
The Economic Times
Like
Reply

Type
Buy
Instrument
ASTRAZEN
Entry Price
₹3,541.3
Price@Trade
₹3,541.3
Target Price
₹3,556  ₹3,579
Stop Price
₹3,533
Valid Till
Jul 15, 2021 3:20 AM
Margin
₹354,130 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹3,533
Net P&L
-₹830 (-0.23%)
Like
Reply (2)
swap_vert
Trade
See all replies

Update
Target Extended
Price @ Update
₹3,545
Original Target
₹3,556
New Target
3579.0
TrackerBot @trackerbot
Jul 15 6:32 AM

Update
Stoploss Hit
Exit Price
₹3,533
N
Reputation: 15,595 • Jul 15 4:16 AM
Big Pharma's COVID-19 reputation boost may not last — here's why
Over the past few months, the world has witnessed rapid clinical trials and approvals of several highly effective vaccines like Pfizer, Moderna and AstraZeneca. This unprecedented achievement has been made possible by close intra-industry, state industry and international collaborations.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 14 3:51 AM
EXPLAINER: Are we going to need COVID-19 booster shots?
Globally, experts are watching closely to determine if and when people might need another shot. At the same time, many suggest the priority for the time being should be vaccinations, noting that worrisome coronavirus mutants wouldn't be popping up so fast if more of the U.S. and the rest of the world had gotten the initial round of shots.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 14 12:41 PM
No application for Covishield yet: EU drug regulator
The EMA website lists four vaccines as under rolling review — Sputnik V, Covovax, CureVac and Sinovac. An SII executive who is familiar with the approval process said the company had applied for approval for Covishield through AstraZeneca.
The Economic Times
Like
Reply
N
Reputation: 15,595 • Jul 13 2:26 AM
In remote Sundarbans, boats full of vaccines bring hope to over 4.5 million people
Home to more than 4.5 million people and the largest mangrove forest in the world, residents of the Bay of Bengal delta endure all the miseries nature throws at them - from cyclones to erosion. But the pandemic is testing a region with only basic healthcare facilities.
The Economic Times
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • ASTRAZEN - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization4,995.75
    Enterprise Value4,822.45
    Price to Earnings89.09
    Price to Book Value16.6
    Return on Capital Employed0.18
    Return on Equity0.11
    Face Value2
    Dividend YieldNA
  • ASTRAZEN - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    30-Nov-17Rudra Shares & Stocks BrokersBuy1,420
    ASTRAZEN Brokerage Price Target
  • ASTRAZEN Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 233533.1535643461.83498.05
    Jul 2235173607.753494.13499.5
    Jul 203490351034813494.65
    Jul 193529.953546.534903498.7
    Jul 1635353558.853505.13517.35
  • ASTRAZEN Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹3,573.61
    30 Day Moving Average₹3,625.75
    50 Day Moving Average₹3,694.29
    100 Day Moving Average₹3,616.91
    200 Day Moving Average₹3,915.31
  • ASTRAZEN - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue571539.570.06
    Operating Profit4629.380.57
    Profit Before Tax4433.20.33
    Net Income2624.440.06
  • ASTRAZEN - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds3012470.22
    Total Liabilities2612150.21
    Total Assets5624620.22
  • ASTRAZEN - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity938.31-0.77
    Cash from Investing Activity-90.25-37
    Cash from Financing ActivityNA-0.22-1
    Net Cash Flow-138.35-1.03
  • ASTRAZEN - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.06
    Return on Equity0.110.14
    Return on Capital Employed0.180.18
  • ASTRAZEN - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit5.03
    3 Year CAGR Growth in EBIDTA11.61
    3 Year CAGR Growth in Net Income2.25
    3 Yr CAGR Growth - Diluted EPS2.26
  • ASTRAZEN - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.46
    5 Year CAGR Growth in Operating Profit1.67
    5 Year CAGR Growth in EBIDTA2.02
    5 Year CAGR Growth in Net Income1.29
    3 Yr CAGR Growth - Diluted EPS1.29
  • ASTRAZEN - Recent News

    keyboard_arrow_down
    NewsBot
    Today 2:11 AM
    UK briefed on COVID-19 situation in India to review 'red list' travel ban
    The Economic Times
    NewsBot
    Today 8:26 AM
    CoronaVac vaccine: its results are patchy, but the world can't ignore its usefulness
    The Economic Times
    NewsBot
    Jul 22 7:21 AM
    Study finds lower antibody activity against delta variant at single dose, but vaccines still work
    The Economic Times
    NewsBot
    Jul 22 2:01 AM
    Asian stocks shrug off virus worries; ECB in focus
    The Economic Times
    NewsBot
    Jul 21 5:06 AM
    Covid-19 pandemic has dimmed the clean power market
    The Economic Times
    NewsBot
    Jul 21 3:06 AM
    Australia, under lockdown, sees jump in COVID-19 cases
    The Economic Times
    NewsBot
    Jul 20 4:21 AM
    The Beta variant: What scientists know right now
    The Economic Times
    NewsBot
    Jul 19 1:16 AM
    Bharat Biotech dossier under review for Covaxin emergency use listing: WHO
    The Economic Times
    NewsBot
    Jul 19 12:41 PM
    AstraZeneca wants Serum Institute of India listed as manufacturing site
    The Economic Times
    NewsBot
    Jul 16 6:06 AM
    India, Bangladesh reaffirm commitment to further strengthen bilateral cooperation
    The Economic Times
  • ASTRAZEN - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020